XEOMINÃ‚® (incobotulinumtoxinA) Data to be Presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation
FRANKFURT, Germany, Nov. 17, 2011 /PRNewswire/ -- Merz Pharmaceuticals today announced that results from five studies examining XEOMIN® (incobotulinumtoxinA), a botulinum neurotoxin type A preparation free from accessory proteins, will be presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Orlando, Fla.
The first poster being presented at the meeting, titled "Sustained efficacy of incobotulinumtoxinA (XEOMIN®; botulinum neurotoxin type A free from accessory proteins) in cervical dystonia demonstrated by investigator and patient-rated outcomes," assessed the long-term efficacy and tolerability of XEOMIN® in cervical dystonia in a setting similar to clinical practice. The prospective, multicenter, open-label single-arm Phase IV study found that XEOMIN® showed sustained efficacy and was well tolerated in the treatment of cervical dystonia for up to 121 weeks. [Poster 130; Dressler, et al.]
The second poster, titled "Significant and sustained efficacy of incobotulinumtoxinA (XEOMIN®; botulinum neurotoxin type A, free from accessory proteins) in upper limb spasticity," included two studies. The first consisted of a randomized, double-blind, placebo-controlled main period and an open-label extension period and evaluated patients with upper limb (UL) post-stroke spasticity. The second was a randomized study of two dilutions of incobotulinumtoxinA that assessed patients with UL spasticity of various etiologies. Study results showed that incobotulinumtoxinA was well tolerated and demonstrated significant, sustained efficacy in UL spasticity. [Poster 138; Kanovsky, et al.]
"The positive findings presented at AAPM&R reinforce that XEOMIN® is a safe and effective option for patients in need of treatment for certain movement disorders," said Petr Kanovsky, MD, PhD, Department of Neurology, Palacky University Medical School, Olomouc, Czech Republic, a